1. Lori, F., Bonati, A., Buscaglia, M., and Starcich, R.: The Phenotype of Terminal Deoxynucleotidyl Transferase Positive Cells in the Hemopoietic Tissues of Human Fetuses. In Torelli, U., Di Prisco, A.U., and Castaldini, C. (Eds.): Frontiers in Experimental Hematology. Rome, Serono Symposia Publications, 1983, pp. 210-219.
2. Lori, F., Casoli, C., Albertini, R., Bonati, A., and Starcich, R.: Analysis of Catalytic Subunits of DNA Polymerase α in Acute Myeloblastic Leukemia. In Cajozzo, A. and Perricone, R. (Eds.): Attualità in Ematologia. Bologna, Monduzzi, 1985, pp. 120-129.
3. Lori, F., Casoli, C., and Starcich, R.: DNA Polymerase α Activity in Acute Leukemia: Comparative Analysis of Catalytic Subunits after SDS-PAGE. Boll. Soc. It. Biol. Sper. 62(10): 1197-1203, 1986.
4. Lori, F., Casoli, C., and Starcich, R.: Heterogeneity of DNA Polymerase α in Embryo Tissues. Boll. Soc. It.al Biol. Sper. 62(10): 1205-1211, 1986.
5. Lori, F., Scovassi, A.I., Brusamolino, E., Casoli, C., and Starcich, R.: Different Expression of DNA Polymerase α and β in Bone Marrow and Peripheral Blood in Acute Leukemia. In Habmont, A.C. (Ed.): Attualità in Ematologia, 1987. Bologna, Monduzzi, 1987, pp. 747-750.
6. Lori, F., Casoli, C., Tremolada, F., Scovassi, I., Bertazzoni, U., Starcich, R., Realdi, G., and Alberti, A.: Detection and Characterization of Reverse Transcriptase Activity in Sera of Patients with Post-transfusion Non-A Non-B Hepatitis. Ital. J. Gastroenter.19: 31, 1987.
7. Lori, F., Casoli, C., Tremolada, F., Scovassi, I., Bertazzoni, U., Starcich, R., and Alberti, A.: Reverse Transcriptase Activity in Post-transfusion Non-A Non-B Hepatitis. I° Characterization and Association with Retrovirus-like Particles. Serodiagnosis and Immunotherapy 1: 339-346, 1987.
8. Lori, F., Scovassi, A.I., Brusamolino, E., Casoli, C., and Starcich, R.: Different Distribution of DNA Polymerases α and β in Bone Marrow and Peripheral Blood from Human Acute Leukemia. Med. Oncol. Tumor Pharmacother. 5(3): 181-186, 1988.
9. Lori, F.., Scovassi, A.I., Zella, D., Achilli, G., Cattaneo, E., Casoli, C., and Bertazzoni, U.: Enzymatically Active Forms of Reverse Transcriptase of the Human Immunodeficiency Virus. AIDS Res. Hum. Retroviruses 4(5): 393-398, 1988.
10. Lori, F., Bertazzoni, U., Achilli, G., and Cattaneo, E.: Assays and Structure of Reverse Transcriptase of the AIDS Virus. Clin. Chim. Acta. 183(1): 101-106, 1989.
11. Lori, F., Achilli, G., Cattaneo, E., Casoli, C., and Bertazzoni, U.: Usefulness of Activity Gel Analysis in the Study of Reverse Transcriptase of HIV-1 and other Retroviruses. Arch. AIDS Res. 4:1-8, 1990.
12. Lori, F., Zella, D., Mori, L., Sala, M., Ferrante, P., Casoli, C., Magnani, G., Achilli, G., Cattaneo, E., and Bertazzoni, U.: HTLV-II Infection in Italian Drug Abusers. Lancet 366(8714): 575-576, 1990.
13. Lori, F., Lusso, P., and Gallo, R.C.: CD-4 Independent Infection by Human Immunodeficiency Virus Type-1 after Phenotyping Mixing with Human T-cell Leukemia Viruses. J. Virol. 64(12): 6341-6344, 1990.
14. Lori, F., Lusso, P., De Maria, A., Malnati, M., DeRocco, S.E., Baseler, M., and Gallo, R.C.: Induction of CD4 and HIV-1 Susceptibility in Human CD8 + T Lymphocytes by HHV-6. Nature 349(6309): 533-535, 1991.
15. Lori, F., Hall, L., Lusso, P., Popovic, M., Markham, P., Franchini, G., and Reitz, M.S., Jr. : Effect of Reciprocal Complementation of two Defective Human Immunodeficiency Virus Type- 1 (HIV-1) Molecular Clones on HIV-1 Cell Tropism and Virulence. J. Virol. 66(9): 5553-5560, 1992.
16. Lori, F., Di Marzo Veronese, F., De Vico, A.L., Lusso, P., Reitz, M.S., and Gallo, R.C.: Viral DNA Carried by HIV-1 Virions. J. Virol. 66(8): 5067-5074, 1992.
17. Lori, F., Zella, D., Cavicchini, A., Salemi, M., Casoli, C., Achilli, G., Cattaneo, E., Landini, V., and Bertazzoni, U.: Molecular Characterization of two Isolates of Human T-cell Leukemia Virus Type-II from Italian Drug Abusers and Comparison of Genome Structure with other Isolates. J. Gen. Virol. 74: 315-319, 1993.
18. Lori, F., Lisziewicz, J., Sun, D., Smythe, J., Lusso, P., Louie, A., Markham, P., Rossi, J., Reitz, M., and Gallo, R.C.: Inhibition of Human Immunodeficiency Virus Type I Replication by Regulated Expression of a Polymeric-TAR RNA Decoy as a Strategy for Gene Therapy. Proc. Natl. Acad. Sci. USA 90(17): 8000-8004, 1993.
19. Gao, W-Y., Cara, A ., Gallo, R.C., and Lori, F.: Low Levels of Deoxynucleotides in Peripheral Blood Lymphocytes: A Strategy to Inhibit Human Immunodeficiency Virus Type-1 Replication. Proc. Natl. Acad. Sci. USA 90(19): 8925-8928, 1993.
20. Lori, F., Lisziewicz, J., Smythe, J., Cara, A., Bunnag, T.A., Curiel, D., and Gallo, R.C.: Rapid Protection Against Human Immunodeficiency Virus Type 1 (HIV-1) Replication Mediated by High Efficiency Non-retroviral Delivery of Genes Interfering with HIV-1 tat and gag. Gene Therapy 1(1): 27-31, 1994
21. Lori, F., Malykh, A., Cara, A., Sun, D., Weinstein, J.N., Lisziewicz, J., and Gallo, R.C.: Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus-type 1 Replication. Science 266(5186): 801-805, 1994.
22. Malykh, A., Louie, A., Hall, L., Reitz, M. and Lori, F.: Multiple Hierarchic Determinants for Growth of HIV-1 in Monocyte-macrophage. Virology 206(1): 646-650, 1995.
23. Cara, A., Guarnaccia, F., Reitz, M.S., Gallo, R.C., and Lori, F.: Self-limiting, Cell-type Dependent Replication of an Integrase Defective HIV-1 in Human Macrophages but not in T-lymphocytes. Virology 208:241-248, 1995.
24. Lori, F., and Gallo, R.C.: Hydroxyurea and AIDS: An Old Drug Finds a New Application? AIDS Res. and Hum. Retroviruses 11(10): 1149-1151, 1995.
25. Villani, P., Maserati, R., Regazzi-Bonora, M., Giacchino, R., and Lori, F.: Pharmacokinetics of Hydroxyurea in Patients Infected with Human Immunodeficiency Virus Type I. J. Clin. Pharmacol. 36(2): 117-121, 1996.
26. Cara, A., Cereseto, A., Lori, F., Reitz, M.: HIV-1 Protein Expression from Synthetic Circles of DNA Mimicking the Extrachromosomal Forms of Viral DNA. The Journal of Biological Chemistry 271(10): 5393-5397, 1996.
27. Lisziewicz, J., Sun, D., Gallo, R., Ensoli, B., and Lori, F.: Efficacy of antitat Gene Therapy in the Presence of High Multiplicity Infection and Inflammatory Cytokines. Human Gene Therapy, 7(18): 2209-2216, 1996.
28. Foli, A., Lori, F., Maserati, R., Tinelli, C., Minoli, L., Lisziewicz, J.: Hydroxyurea (HU) and Didanosine (ddI) as a More Potent Combination than HU and Zidovudine (AZT). An In Vitro Prediction in Confirmed in Vivo. Antiviral Therapy 2:31-38, 1997.
29. Lori, F., Jessen, H., Foli, A., and Lisziewicz, J.: Long Term Suppression of HIV-1 by Hydroxyurea and Didanosine. JAMA 277(18): 1437-38, 1997.
30. De Antoni, A., Foli, A., Lisziewicz, J., Lori , F.: Mutations in the pol Gene of Human Immunodeficiency Virus Type 1 in Infected Patients Receiving Didanosine and Hydroxyurea Combination Therapy. J of Infectious Diseases 176:899-903, 1997.
31. Lori, F., Gallo, R.C., Malykh, A., Cara, A., Romano, J., Markham, P.: Didanosine but not High Doses of Hydroxyurea Rescue Pigtailed Macaque from a Lethal Dose of SIVsmmpbj14. AIDS Research and Human Retroviruses, 13(13): 1083-88, 1997.
32. Lori, F., Malykh, A., Foli, A., Maserati, R., De Antoni, A., Minoli, L., Padrini, D., Degli Antoni, A., Baerchi, E., Jessen, H., Wainberg, M., Gallo, R., Lisziewicz, J.: Combination of a Drug Targeting the Cell with a Drug Targeting the Virus Controls Human Immunodeficiency Virus Type 1 Resistance. AIDS Research and Hum. Retroviruses 13(16):1403-1409, 1997.
33. Foli, A., Maserati, R., Minoli, L., Wainberg, M.A., Gallo, R.C., Lisziewicz, J., Lori, F.: Therapeutic Advantage of Hydroxyurea and Didanosine Combination Therapy in Patients Treated with Zidovudine. AIDS, 1998.
34. Lisziewicz, J., Jessen, H., Finzi, D., Siliciano, R.F., Lori, F.: HIV-1 Suppression by Early Treatment with Hydroxyurea, Didanosine, and a Protease Inhibitor. Lancet 352(9123): 199-200, 1998.
35. Lori, F., Lisziewicz J.: Cellular Factors: Targets for the Treatment of HIV Infection. Antiviral Therapy 3:79-90, 1998.
36. Lori, F., Lisziewicz, J.: Hydroxyurea: Mechanisms of HIV-1 Inhibition. Antiviral Therapy 3 (Supplement 4): 26-33, 1998.
37. Boyer P.L., Lisziewicz, J., Lori, F., Hughes, S.H.: Analysis of Amino Insertion Mutations in the Fingers Subdomain of HIV-1 Reverse Transcriptase. Journal of Molecular Biology 286(4): 995-1008, 1999.
38. Finzi, D., Blankson, J., Siliciano, J.D., Margolick, J.B., Chadwick, K., Pierson, T., Smith, K., Lisziewicz, J., Siliciano, R.F.: Latent Infection of CD4+ T Cells Provides a Mechanism for Lifelong Persistence of HIV-1, Even in Patients on Effective Combination Therapy. Nature Medicine (5)5: 512-517, 1999.
39. Foli, A. and Lori, F.: Hydroxyurea Combination Therapy. Journal of HIV Therapy. 4(2): 45-48, 1999.
40. D’Aquila, R.T., Johnson, V.A., Lori, F., Palmer, S.: Drug Resistance and Pathogenesis: Clinical Implications of New Data. Massachusetts General Hospital, 1-17, 1999.
41. Lori, F., Jessen, H., Lieberman, J., Clerici, M., Tinelli, C., Lisziewicz, J: Immune Restoration by Combination of a Cytostatic Drug (Hydroxyurea) and Anti-HIV Drugs (ddI and Indinavir). AIDS Res Human Retroviruses, 15 (7): 619-624, 1999.
42. Lisziewicz, J., Rosenberg, E., Lieberman, J., Jessen, H., Lopalco, L., Siliciano, R., Walker, B. and Lori, F.: Control of HIV Despite the Discontinuation of Antiretroviral Therapy. New England J of Medicine. 340(21): 1683-4, 1999.
43. Lori, F.: Hydroxyurea and HIV: 5 Years Later-- From Antiviral to Immune-modulating Effects. AIDS. 13(12): 1433-42, 1999.
44. Seminari, E., Lisziewicz, J., Tinelli, C., Foli, A., Lori, F., Maserati, R.: Hydroxyurea Toxicity when Combined with Didanosine (ddI)- in HIV-1 Seropositive Asymptomatic Individuals. Int'l J. of Clin Pharmaceutical and Therapeutics. 37(10): 514-518, 1999.
45. Lori, F.: Hydroxyurea for the Therapy of HIV Infection: From Antiviral to Immune-Modulating Effects. The PRN Notebook. 4(2): 9-12, June 4, 1999.
46. Ravot, E., Lisziewicz, J., and Lori, F.: New Uses for Old Drugs in HIV Infection: The Role of Hydroxyurea, Cyclosporin and Thalidomide. Drugs. 58(6): 953-63, 1999.
47. Lisziewicz, J., and Lori, F.: Mechanisms of Human Immunodeficiency Virus Type I Inhibition by Hydroxyurea. Journal of Biological Regulators and Homeostatic Agents, 1999.13(3): 176-80, 1999 Review.
48. Lori, F., Jessen, H., Lieberman, J., Finzi, D., Rosenberg, E., Tinelli, C., Siliciano, R., Walker, B., and Lisziewicz, J.: Treatment of Human Immunodeficiency Virus Infection with Hydroxyurea, Didanosine, and a Protease Inhibitor before Seroconversion is Associated with Normalized Immune Parameters and Limited Viral Reservoir. Journal of Infectious Diseases. 180(6): 1827-1832, 1999.
49. Lori, F., and Lisziewicz, J.: Role of Immune Modulation in Primary HIV Infection. Journal of Biological Regulators and Homeostatic Agents. 25: 45-48, 2000.
50. Lori, F., Rosenberg, E., Lieberman, J., Foli, A., Maserati, R., Seminari, E., Alberici, F., Walker, B., Lisziewicz, J.: Hydroxyurea and Didanosine Long-Term Treatment Prevents Breakthrough and Normalizes Immune Parameters. AIDS Res. Hum Retr, 15(15): 1333-1338, 1999.
51. Lieberman, J., Trimble, L.A., Friedman, R.S., Lisziewicz, J., Lori, F., Shankar, P., Jessen, H.: Expansion of CD57 and CD62L-CD45RA+CD8 T Lymphocytes Correlates with Reduced Viral Plasma RNA after Primary HIV Infection. AIDS 13(8) 1999.
52. Lori, F., and Lisciewicz, J.: Targeting HIV Reservoirs and Reconstituting the Immune System. AIDS Research and Human Retroviruses. 15(18): 1597-1617, 1999.
53. Boyer, P.L., Lisziewicz, J., Lori, F., Hughes, S.H.: Analysis of Amino Insertion Mutations in the Fingers Subdomain of HIV-1 Reverse Transcriptase. J. of Molecular Biology 286,995-1008, 1999.
54. Lori, F., and Lisziewicz, J.: Hydroxyurea Overview of Clinical Data and Antiretroviral and Immunomodulatory Effects. Antiviral Therapy. 4(3): 101-108, 1999.
55. Lori, F., Maserati, R., Foli, A., Seminari, E., Timpone, J., Lisziewicz, J.: Structured Treatment Interruptions to Control HIV-1Infection, The Lancet, 355(9200): 287-288, 2000.
56. Lisziewicz, J., Zeng, G., Gratas, C., Weinstein, J.N., Lori, F.: Combination Gene Therapy: Synergystic Inhibition of Human Immunodeficiency Virus Tat and Rev Functions by a Single RNA Molecule. Human Gene Therapy. 11: 807-815, 2000.
57. Barreio, P. and Lori, F.: The Role of Hydroxyurea in the Treatment of HIV Infection. AIDS Reviews. (2)99-104, 2000.
58. Lori, F., and Lisziewicz, J.: Rationale for the Use of Hydroxyurea as Anti-Human Immunodeficiency Virus Drug. Clinical Infectious Diseases, 30(S2): S193-S197, 2000.
59. Ravot, E., Tambussi, G., Jessen, H., Tinelli, C., Lazzarin, A., Lisziewicz, J., Lori, F.: Effects of Hydroxyurea on T Cell Count Changes During Primary HIV Infection. AIDS 14(5): 619-622, 2000.
60. Lori, F., Lewis, M.G., Xu, J., Varga, G., Zinn, D.E., Crabbs, C., Wagner, W., Greenhouse, J., Silvera, P., Yalley-Ogunro, J., Lisziewicz, J.: Control of SIV Rebound Through Structured Treatment Interruptions During Early Infection. Science 290(5496): 1591-1593, 2000.
61. Foli, A., Benvenuto, F., Piccinini, G., Bareggi, A., Cossarizza, A., Lisziewicz, J., and Lori, F.: Direct analysis of mitochondrial toxicity of antiretroviral drugs. AIDS. Sep. 2001 15(13), 1687-1694, 2001.
62. Lisziewic, J., Gabrilovich, DI, Varga, G., Xu, J., Greenberg, PD., Arya, SK, Bosch, M., Behr, JP. and Lori, F.: Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells. J. Virol. Aug. 2001 75(16): 7621-8, 2001.
63. Lori, F., and Lisziewicz, J.: Structured Treatment Interruptions for the Management of HIV Infection in 2001. JAMA. Dec 19;286(23): 2981-7, 2001.
64. Lisziewicz, J., Galluzzi, L., and Lori, F.: Gene Therapy for HIV-1. Bundesgesundheitsbl 44:1071-1075, 2001.
65. Lori, F., and Lisziewicz , J.: Structured Treatment Interruptions for HIV-AIDS therapy. International Antiviral News 2001 9(7): 118-120, 2001.
66. Piccinini, G., Foli, A., Comolli, G., Lisziewicz, J., and Lori, F.: Complementary Antiviral Efficacy of Hydroxyurea and Protease Inhibitors in HIV-Infected Dendritic Cells and Lymphocytes. J. Virol. Mar; 76(5): 2274-8, 2002.
67. Xu, J., Whitman, L., Lori, F., and Lisziewicz, J.: Methods of Using IL-2 to Enhance HIV-specific Immune Responses. AIDS Research and Human Retroviruses. Mar; 18(4): 289-293, 2002.
68. Lisziewicz, J., and Lori, F.: Structured Treatment Interruptions in HIV/AIDS Therapy. Journal of Microbes and Infection. Feb; 4(2): 207-14, 2002.
69. Ravot, E., Comolli, G., Lori, F., and Lisziewicz, J.: High efficiency lentiviral gene delivery in non-dividing cells by deoxynucleoside treatment. Journal of Gene Medicine. Mar-Apr; 4(2): 161-9, 2002.
70. Lori, F., Foli, A., Maserati R., Seminari, E., Xu, J., Whitman, L., Ravot, E., Alberici, F., Lopalco, L., and Lisziewicz, J.: Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses. HIV Clinical Trials Mar-Apr;3(2): 115-24, 2002.
71. Foli, A., Seminari, E., Ravot, E., Lisziewicz, J., and Lori, F. : Role of Hydroxyurea During Structured Treatment Interruptions. Journal of Biological Regulators and Homeostatic Agents Jan-Mar;16(1): 64-8, 2002.
72. Lori, F., Foli, A., and Lisziewicz, J.: Structured Treatment Interruptions as a Potential Alternative Therapeutic Regimen for HIV Infected Patients: a Review of Recent Clinical Data and Future Prospects. Journal of Antimicrobial Agents. 50:155-160, 2002.
73. Xu, J., Whitman, L., Lori, F., and Lisziewicz, J.: Quantification of HIV-specific CD8+ T Cells by in vitro Simulation of Viral Rebound. AIDS. 16(14): 1849-1858, 2002.
74. Lori, F., Guallini, P., Galluzzi, L. and Liszievicz, J.: Gene Therapy Approaches to HIV Infection. Pharmacogenomics. 2(4): 245-52, 2002.
75. Lisziewicz, J., Bakare, N., Lori, F.: Vaccination for the treatment of HIV/AIDS. Vaccine. Jan 30;21(7-8): 620-3, 2003.
76. Garcia, F., Plana, M., Arnedo, M., Ortiz, GM., Miro, JM., Lopalco, L., Lori, F., Pumarola, T., Gallart, T., Gatell, JM.: A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. AIDS. Jan 3;17(1): 43-51, 2003.
77. Xu, J., Lori, F., Lisziewicz, J.: Vaccinia assay for the rapid detection of functional HIV-specific CD8+ cytotoxic T lymphocytes. J Immunol Methods. 276(1-2): 45-57, 2003.
78. Lisziewicz, J., Wainberg, M., and Lori, F.: Is There a Role for Hydroxyurea in the Treatment of HIV Infection? Drug Safety. 26(9): 605-24, 2003.
79. Lisziewicz, J. and Lori, F.: Meeting Highlights: 2nd International Symposium on Molecular Diagnostics and Skin Gene Therapy. Expert Opinion on Biological Therapy (EOBT). Jul;3(4): 683-7, 2003.
80. Lori, F., Kelly, L.M., and Lisziewicz, J.: Immunological Approaches for HIV Gene Therapy. Curr Drug Targets Infect Disord. Jun;3(2): 171-8, 2003.
81. Richardson, MW., Sverstiuk, AE., Silvera, P., Greenhouse, J., Lisziewicz, J., Lori , F., Khalili, K., Lewis, MG., Rappaport, J.: T-cell receptor excision circles (TREC) in SHIV 89.6p and SIVmac251 models of HIV-1 infection. DNA Cell Biol. Jan;23(1): 1-13, 2004.
82. Lori, F., Maserati, R., Foli, A., Barasolo, G., Castelli, F., Tomasoni, L., Migliorino, M., Maggiolo, F., Pan, A., Paolucci, S., Scudeller, L., Tinelli, C., D’Aquilla, R., Lisziewicz, J.: Strategies to decrease viral load rebound and prevent loss of CD4 and onset of resistance during structured treatment interruptions. Antiviral Therapy. Feb;9(1): 123-32, 2004.
83. Lori, F., Maserati, R, Lisziewicz, J, Minoli, L.: Immune reconstitution and control of HIV. HIV Clin Trials. May-Jun;5(3): 170-82, 2004.
84. Lori F., Kelly, L.M., Foli, A., Lisziewicz, J.: Safety of hydroxyurea in the treatment of HIV infection. Expert Opin Drug Saf. Jul;3(4): 279-88, 2004.
85. Lori, F., Kelly L.M., Lisziewicz, J.: APC-targeted immunization for the treatment of HIV-1. Expert Rev Vaccines. Aug;3(4 Suppl): S189-98, 2004.
86. Kelly, L.M., Lisziewicz, J., Lori, F.: “Virostatics” as a Potential New Class of HIV Drugs. Current Pharmaceutical Design, 10(32): 4103-20, 2004.
87. Lisziewicz, J., Trocio, J., Whitman, L., Varga, G., Xu, J., Bakare, N., Erbacher, P., Fox, C., Woodward, R., Markham, P., Arya, S. Behr, J.P., Lori, F.: DermaVir: A Novel Topical Vaccine for HIV/AIDS. Journal of Investigative Dermatology, Jan;124(1): 160-9, 2005.
88. Lisziewicz, J., Lewis, MG, Trocio, J. Xu, J., Whitman, L., Wagner, W., Pistorio, A., Arya, S., and Lori, F.: Control of viral Rebound through Therapeutic Immunization with DermaVir. AIDS, Jan 3;19(1): 35-43, 2005.
89. Lova, L., Groff, A., Ravot, E., Comolli, G., Xu, J., Whitman, L., Lewis, M., Foli, A., Lisziewicz, J., Lori, F.: Hydroxyurea exerts a cytostatic but not immunosuppressive effect on T lymphocytes. AIDS, Jan 28;19(2): 137-144, 2005.
90. Lori, F., Trocio, J., Bakare, N., Kelly, L.M., Lisziewicz, J.: DermaVir, a novel HIV immunisation technology. Vaccine. Mar 18;23(17-18): 2030-4, 2005.
91. Lori, F.: HIV DART 2004-frontiers in drug development for antiretroviral therapies. 12-16 December 2004, Montego Bay, Jamaica. IDrugs. Feb;8(2): 97-9, 2005.
92. Lori, F., Pollard, R.B., Whitman, L., Bakare, N., Blick, G., Shalit, P., Foli, A., Peterson, D., Tennenberg, A., Schrader, S., Rashbaum, B., Farthing, C., Herman, D., Norris, D., Greiger, P., Frank, I., Groff, A., Lova,, L., Asmuth, D., Lisziewicz, J..: Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. AIDS Res Hum Retroviruses. 21(4): 263-272, 2005.
93. Lori, F., Foli, A., Groff, A., Lova, L. MS, Whitman, L., Bakare, N., Pollard, R.B., Lisziewicz, J.: Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms AIDS. Jul 22;19(11): 1173-8, 2005.
94. Lisziewicz, J., Kelly, L.M., Lori, F.: Topical DermaVir vaccine targeting dendritic cells. Curr Drug Deliv. Jan 3(1): 83-8, 2006.
95. Lori, F., Weiner, D.B., Calarota, S.A., Kelly, L.M., Lisziewicz, J.: Cytokine-adjuvanted HIV-DNA vaccination strategies. Springer Semin Immunopathol. Nov 28(3):231-8, 2006.
96. Xu, J.O., Lori, F., Lisziewicz, J.: CD4+ T cell-mediated presentation of non-infectious HIV-1 virion antigens to HIV-specific CD8+ T cells. Chin Med J (Engl) Oct 5;119(19): 1629-38, 2006.
97. Lori, F., Foli, A., Lisziewicz, J.: Stopping HAART temporarily in the absence of virus rebound: exploring new HIV treatment options. Current Opinion in HIV and AIDS 2:14-20, 2007.
98. Lori, F., Foli, A., Kelly, L.M., Lisziewicz, J.: Virostatics: A New Class of Anti-HIV Drugs. Curr Med Chem. 14: 233-41, 2007.
99. Maserati, R., Foli, A., Tomasoni, L., Sighinolfi, L., Maggiolo, F., Sacchini, D., Di Pietro, M., Bertelli, D., Tinelli, C., and Lori, F.: Effects of Structured Treatment Interruptions on Metabolilc, Anthrompometric, Immunologic, and Quality of Life Outcomes in HIV-Positive Adults on HAART. Current HIV Research 5:337-43, 2007.
|
